PEPTIDE TRACKING

21 compounds.
One complete record.

Kinosis tracks every property of your peptide protocol — dose, route, cycle position, vendor, biomarkers, and daily subjective outcomes — in one structured record.

Most peptides tracked here are research compounds not approved by the FDA for human use. Kinosis tracks user-reported protocol data only. Nothing here constitutes medical advice, dosing recommendations, or endorsement of any substance. Consult a licensed healthcare provider before beginning any peptide protocol.

[SEC_01] UNIVERSAL TRACKING

Tracked for every compound, every dose.

Per-dose log

PeptideSelect from catalog · 21 compounds

Dosemcg or mg · unit defined per compound

RouteSC · IM · Intranasal · Topical · Oral

Injection siteAbdomen · Thigh · Arm · Other

Time of dayLogged automatically from entry time

Fasted stateYes / No · relevant for GH secretagogues

StatusTaken · Skipped · Missed

Source & purity

VendorName of supplier

Batch / lotFor contamination clustering

COA availableCertificate of Analysis on file

COA purity %e.g. 99.1% from HPLC / mass spec

Source typeCompounding pharmacy · Research vendor

ReconstitutionMedium · Date reconstituted · Days remaining

Structured source tracking lets reported side effects be compared by vendor and batch.

Protocol change log

Every addition, removal, or modification to an active peptide protocol is timestamped. When you add compound B three weeks into a cycle, Kinosis knows — and your efficacy correlation is measured relative to that change date, not some arbitrary calendar anchor.

Added Removed Dose changed Frequency changed Previous value → New value Reason (optional)

[SEC_02] TIER 1 — CORE

Widely used · Broad use cases

REPAIR & RECOVERY

BPC-157 (Body Protection Compound-157)

250–500 mcg SC · IM · Oral · Intranasal Low tolerance risk

Primary goals

Tissue repair · GI healing · Joint recovery · Systemic inflammation reduction

Cycle

Commonly reported: continuous 12+ weeks · No established off period

Common stacks

TB-500 (Wolverine Stack) · KPV (GI focus)

Biomarkers tracked

hs-CRP · Pain score (1–10) · Energy level

Side effects monitored

Injection site inflammation · Herxheimer response (early cycle)

REPAIR & RECOVERY

TB-500 (Thymosin Beta-4)

2–5 mg SC · IM · Twice weekly Low–Med tolerance risk

Primary goals

Musculoskeletal recovery · Flexibility · Inflammation

Cycle

Commonly reported: 12–16 week blocks · 4 weeks off

Common stacks

BPC-157 (standard repair stack)

Biomarkers tracked

hs-CRP · Pain score · Range of motion

Reconstitution

Bacteriostatic water · Refrigerated · 30 days

GH SECRETAGOGUE

CJC-1295

100–300 mcg SC · Evening fasted High — cycling commonly reported

Primary goals

GH/IGF-1 elevation · Sleep quality · Body composition · Recovery

Heavy meals are reported to blunt the GH pulse; fasted dosing is the commonly reported timing.

Cycle

Commonly reported: 8–12 weeks on · 4 weeks off (tachyphylaxis)

Common stacks

Usually paired with Ipamorelin

Biomarkers tracked

IGF-1 · TSH · Free T3 · Cortisol · Body composition

Side effects monitored

Carpal tunnel · Water retention · Thyroid suppression · BP · Numbness

GH SECRETAGOGUE

Ipamorelin

250–300 mcg SC · Evening fasted High — cycling commonly reported

Primary goals

GH pulse stimulation · Minimal cortisol/prolactin elevation vs. other GH secretagogues

Cycle

Commonly reported: 8–12 weeks on · 4 weeks off

Common stacks

CJC-1295 (usually paired)

Biomarkers tracked

IGF-1 · Cortisol · Prolactin

Side effects monitored

Water retention · Mild joint pain early in cycle

GH SECRETAGOGUE

Sermorelin (GHRH 1-29 Analog)

200–300 mcg SC · Bedtime fasted Moderate — IGF-1 commonly rechecked

Primary goals

GH pulse support · IGF-1 support · Sleep quality · Body composition · Recovery

Same receptor class as FDA-approved tesamorelin; it acts on the GHRH signal rather than replacing GH.

Cycle

Commonly reported: 5 nights/week at bedtime · 3–6 months, with an IGF-1 recheck

Common stacks

Ipamorelin (GHRH + GHRP pairing)

Biomarkers tracked

IGF-1 · Fasting glucose · HbA1c · Body composition · Sleep metrics

Side effects monitored

Injection-site reactions · Flushing · Headache · Water retention · Contraindicated with active/prior cancer

ANTI-AGING / COGNITIVE

GHK-Cu (Copper Peptide)

1–2 mg SC · Topical · Oral Medium tolerance risk

Primary goals

Collagen production · Skin quality · Anti-aging · Cognitive clarity · Neurovascular function

Cycle

Commonly reported: 4–6 weeks on · 2 weeks off (receptor desensitization)

Common stacks

Epithalon (regenerative stack) · Semax (cognitive stack)

Biomarkers tracked

Skin quality (subjective) · Cognitive function score · HRV

[SEC_03] TIER 2 — COGNITIVE

Intranasal delivery · Rapid tachyphylaxis · Cycling commonly reported

COGNITIVE ENHANCEMENT

Semax (ACTH 4-7 Analog)

250–600 mcg Intranasal · Morning/afternoon High — rapid buildup

Primary goals

Cognitive performance · Focus · Memory · Learning · Stress resilience

Commonly taken before 3pm; users report the stimulatory effect can disrupt sleep.

Cycle

Commonly reported: 4–6 weeks on · 2 weeks off

Common stacks

Selank (balanced cognitive + mood) · GHK-Cu

Biomarkers tracked

Cognitive score · HRV · Sleep quality

Side effects monitored

Overstimulation · Tolerance headaches · Sleep disruption

COGNITIVE / MOOD

Selank (Tuftsin Analog)

250–600 mcg Intranasal · Morning/afternoon High tolerance risk

Primary goals

Anxiety reduction · Mood stabilization · Emotional regulation · Sleep quality

Cycle

Commonly reported: 4–6 weeks on · 2 weeks off

Common stacks

Semax (Semax for performance, Selank for mood)

Biomarkers tracked

Anxiety score (1–10) · Sleep quality · HRV

Side effects monitored

Tolerance · Rebound anxiety on cessation

[SEC_04] TIER 3 — LONGEVITY / MITOCHONDRIAL

Long cycles · Low tolerance risk · Biological aging mechanisms

LONGEVITY / ANTI-AGING

Epithalon

5–10 mg/day · SC · 6–12+ months

Telomere support · Sleep-wake cycle regulation · Anti-aging

Biomarkers

Sleep quality · HRV · Melatonin · Energy

Common stacks

GHK-Cu · MOTS-c + SS-31

MITOCHONDRIAL HEALTH

SS-31 (Elamipretide)

0.5–2 mg · SC · 1–3x weekly

Mitochondrial efficiency · Energy production · Metabolic optimization

Biomarkers

Energy level · VO₂ max · HRV · Exercise capacity

Common stacks

MOTS-c (mitochondrial stack)

MITOCHONDRIAL / METABOLIC

MOTS-c

1–5 mg · SC · 1–3x weekly

Insulin sensitivity · Fat oxidation · Metabolic optimization · Exercise capacity

Biomarkers

Fasting glucose · Fasting insulin · HbA1c · Body composition · HRV

Common stacks

SS-31 · AOD-9604

ANTIOXIDANT / DETOX

Glutathione

200 mg · SC / Intranasal · 2–3x weekly

Antioxidant tripeptide · Oxidative stress · Immune support · Skin tone

Biomarkers

Energy level · Skin quality · hs-CRP · Liver enzymes (ALT/AST)

Common stacks

NAD+ · NAC (oral precursor)

[SEC_05] TIER 4 — IMMUNE

Immune modulation · Inflammation · Wound healing

IMMUNE MODULATION

Thymosin Alpha-1

1–1.6 mg · SC · 1–3x weekly

T-cell/NK cell activity · Immune function · Vaccine response

Biomarkers

Infection frequency log · Energy · Inflammatory markers

ANTI-INFLAMMATORY / GI

KPV (Lys-Pro-Val)

100–500 mcg · SC/Topical · Daily–2x daily

NF-κB inhibition · GI inflammation · Gut barrier integrity

Biomarkers

GI symptom score · hs-CRP · Stool consistency

IMMUNE / WOUND HEALING

LL-37 (Human Cathelicidin)

250–500 mcg · SC/Topical · 2–3x weekly

Antimicrobial defense · Wound healing · Angiogenesis

Biomarkers

Wound healing rate · Infection frequency · hs-CRP

[SEC_06] TIER 5 — FAT LOSS / METABOLIC

Selective lipolysis · Fasted dosing commonly reported

FAT LOSS / METABOLIC

AOD-9604 (GH Fragment 176-191)

100–300 mcg SC · Morning or evening fasted Medium tolerance risk

Primary goals

Fat loss · Metabolic health · Reported to have less effect on IGF-1 than full GH secretagogues

Cycle

Commonly reported: 8–12 weeks on · 2–4 weeks off

Common stacks

MOTS-c (metabolic stack) · CJC-1295/Ipamorelin (body composition)

Biomarkers tracked

Body composition · Fasting glucose · Lipid panel

[SEC_07] TIER 6 — NEXT-GENERATION GLP-1 / HORMONAL

Newer and approved compounds · Weekly or daily injections · Metabolic markers

GLP-1 / WEIGHT LOSS

Retatrutide

4–12 mg SC · Once weekly Low tolerance risk

Primary goals

Weight loss (up to 29% in trials) · Fatty liver · Metabolic health · Triple receptor: GLP-1 + GIP + glucagon

Status

Not FDA approved — late-stage clinical trials. Ongoing protocol, no established off period.

Biomarkers tracked

Body weight · Fasting glucose · HbA1c · ALT/AST · Lipid panel · Waist circumference

Daily check-in

Hunger score · Craving intensity · Nausea · GI comfort

GH SECRETAGOGUE / VISCERAL FAT

Tesamorelin FDA approved for HIV-associated lipodystrophy · widely used off-label

1–2 mg SC · Evening fasted Medium tolerance risk

Primary goals

Visceral fat reduction · IGF-1 elevation · Body composition · Metabolic health

Cycle

Commonly reported: 12–26 weeks, then an off period · Reconstitution: 21 days

Biomarkers tracked

IGF-1 · Waist circumference · Body composition · Fasting glucose · HbA1c

Side effects monitored

Fluid retention · Joint pain · Carpal tunnel · Blood glucose elevation

LONGEVITY / MITOCHONDRIAL / NEUROPROTECTION

Humanin

100–500 mcg SC · Intranasal · 2–3x weekly Low tolerance risk

Primary goals

Neuroprotection research · Metabolic health · Mitochondrial function

Encoded in mitochondrial DNA. Circulating levels decline with age. Human outcome data is limited.

Cycle

Commonly reported: 12+ weeks · Long-term use being studied

Common stacks

SS-31 + MOTS-c (mitochondrial longevity) · Epithalon

Biomarkers tracked

Cognitive score · Energy · HRV · Fasting insulin · IGF-1

BRAIN / APPETITE / EMOTIONAL HEALTH

Oxytocin FDA approved for obstetric use · intranasal off-label

20–40 IU Intranasal · Before meals / morning Low–Med tolerance risk

Primary goals

Emotional eating · Satiety · Social bonding · Stress. Studied as a satiety signal, a different mechanism from GLP-1.

Cycle

Commonly reported: continuous or as needed · No established cycle

Common stacks

Selank (stress + emotional eating)

Biomarkers tracked

Meal frequency · Caloric intake · Anxiety score · Weight

Side effects monitored

Headache · Nausea · Rebound emotional sensitivity on cessation

BRAIN / LIBIDO / REWARD SYSTEM

PT-141 (Bremelanotide) FDA approved for HSDD

1.75 mg SC · Intranasal · As needed Low tolerance risk

Primary goals

Libido · Sexual function · Brain reward system modulation. Acts on melanocortin receptors in the brain — relevant to longevity users tracking hormonal health and quality of life markers.

Dosing

Commonly reported: as needed, 45 min before activity · Label maximum 1x per 24h

Common stacks

GHK-Cu (skin/systemic) · Selank (mood support)

Biomarkers tracked

Libido score (subjective) · Mood · Energy

Side effects monitored

Nausea · Flushing · Transient BP increase · Hyperpigmentation with repeated use

[SEC_08] AGGREGATED EFFICACY

Toward a structured peptide evidence base.

Many people run peptide protocols with no aggregated outcome data to reference.

Because every Kinosis peptide protocol is structured — defined compounds, tracked doses, measured biomarkers — data from people running similar protocols can be anonymized and aggregated once enough people contribute. Reports describe what was logged; they are not clinical evidence.

Per-peptide efficacy report includes

Number of users tracking (anonymized count)
Average adherence rate and most common dose
Biomarker trends at 4, 8, and 12 weeks
Subjective outcome trends (pain, energy, focus)
Reported side effect frequency
Most common transition protocols after cycling off

Minimum threshold: 50 users with ≥4 weeks of data before a peptide appears in public reports.

GET STARTED

Track your peptide protocol.

Log via conversation — "I took 300mcg BPC-157 this morning, subcutaneous." Kinosis extracts the compound, dose, route, and time automatically.

Download the App Try on WhatsApp

Kinosis is free · Works in any language · No credit card needed